Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed ...

Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to Neutral. Analyst Price Forecast Suggests 107.09% Upside As of April 1, 2025, ...

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price cut by The Goldman Sachs Group from $18.00 to $14.00 in a research report report published on Thursday morning,Benzinga reports.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...

MYGN has been the topic of several other reports. Bank of America dropped their price target on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...